Connect with us

Press Release

Strativerse Ai Launches New AI Pine Script Generator for Faster Strategy Development

Published

2 months ago

on

London, United Kingdom, 16th Sep 2026 – The increasing use of artificial intelligence in financial software is changing how traders approach the technical side of strategy development, particularly as market participants look for more efficient ways to translate trading concepts into testable code. Against this backdrop, Strativerse.Ai has launched a new AI Pine Script Generator designed to help users move from plain-language trading instructions to structured Pine Script code more efficiently. The launch expands the company’s broader strategy-development environment at a time when algorithmic trading tools are becoming accessible to a wider range of users beyond professional quantitative teams and experienced software developers. Traders who understand indicators, market conditions, entry rules, exit criteria, and risk controls may still encounter a technical barrier when attempting to express those ideas programmatically. Strativerse.Ai is addressing that gap by providing a natural-language workflow in which the user defines the intended strategy logic before artificial intelligence interprets those instructions and generates corresponding code. The technology is intended to support the development process rather than replace the testing, validation, and market judgment required before any algorithmic strategy is considered for practical use.

The new AI Pine Script Generator sits within a broader set of development capabilities offered by Strativerse.Ai, including its AI Trading Strategy Generator and support for Pine Script, Python, and C#. The workflow begins with the trader explaining how a strategy should operate in ordinary language. That description can include technical indicators, price conditions, trade direction, entry criteria, exit logic, stop-loss rules, or other parameters relevant to the strategy. The platform then translates those requirements into structured code that can be reviewed and refined. This approach can reduce the amount of time spent manually writing syntax while allowing users to concentrate more closely on the underlying logic of the strategy itself. For experienced programmers, AI-assisted generation can serve as a starting point for development and iteration. For users with limited programming backgrounds, it can provide a more accessible route into systematic strategy construction. In both cases, the generated code remains something that should be examined carefully, tested against appropriate data, and assessed for whether it accurately represents the original trading instructions.

The launch also reflects a wider shift in financial technology toward natural-language interfaces that can connect specialist knowledge with software implementation. A trader may have a clearly defined view of how a strategy should react to market conditions but lack the programming expertise needed to convert that framework into functioning code. Through its Trading Strategy Code Generator, Strativerse.Ai is designed to shorten that translation process. Instead of starting with programming syntax, users can begin with the rules they want the strategy to follow. A typical use case might involve defining a combination of technical indicators, establishing conditions under which a position should be opened, specifying when it should be closed, and incorporating risk-management parameters. The resulting code can then become the basis for further testing and refinement. This model is increasingly relevant as algorithmic trading expands beyond institutional desks and into broader segments of the market. The availability of programmable trading environments has created demand for tools that can make code development more understandable without removing the discipline required to evaluate how a strategy behaves across changing market conditions.

From a product-development perspective, the new capability also strengthens the relationship between the company’s AI Pine Script Generator and its Trading Bot From Text functionality. Strativerse.Ai allows users to begin with a written description of a trading idea rather than a blank coding environment, giving the system a defined set of rules to interpret. This text-first structure is particularly relevant to the broader adoption of generative AI, where natural-language instructions are increasingly being used to perform technical tasks that once required extensive manual coding. In trading, however, accuracy is especially important. Small differences in conditions, logical operators, timing assumptions, or execution rules can materially change how a strategy behaves. For that reason, AI-generated code should be treated as a development output that requires human review rather than as an automatically validated trading system. The platform’s role is to make strategy construction more efficient while keeping responsibility for analysis, testing, and risk decisions with the user. That distinction is important as financial software providers seek to apply AI capabilities without overstating what automated systems can reliably determine on behalf of traders.

The commercial and strategic relevance of the launch extends beyond Pine Script itself. As traders adopt increasingly systematic approaches to decision-making, demand is growing for tools that can support faster experimentation across different strategy concepts and programming environments. Strativerse.Ai is positioning the AI Trading Strategy Generator, AI Pine Script Generator, Trading Strategy Code Generator, and Trading Bot From Text as connected components of a broader development workflow rather than isolated features. The common principle is the conversion of clearly expressed trading logic into structured code that can then be tested and improved. This model aligns with the broader direction of AI-assisted software development, where artificial intelligence is increasingly being used to accelerate coding tasks while human users retain responsibility for defining objectives and evaluating outputs. For financial markets, where conditions can change quickly and historical results do not ensure future performance, that balance remains critical. Faster code creation may improve the efficiency of experimentation, but the quality of a trading strategy ultimately depends on its logic, testing methodology, assumptions, risk parameters, and suitability for the market environment in which it is used.

For Strativerse.Ai, the launch represents a continued focus on reducing the technical friction involved in moving from a trading concept to a programmable strategy. The AI Pine Script Generator provides a direct route for traders who want to work within Pine Script, while the platform’s wider architecture supports users whose development requirements involve Python or C#. The growing adoption of AI-assisted development tools suggests that traders will increasingly expect financial technology platforms to understand instructions expressed in natural language and convert them into technically useful outputs. At the same time, sophisticated users are likely to judge these platforms not simply by the speed of generation, but by how accurately they interpret instructions, how clearly the resulting code can be reviewed, and how effectively the workflow supports iteration. The long-term opportunity for platforms such as Strativerse.Ai therefore lies in making algorithmic strategy development more accessible while retaining the analytical discipline that serious trading systems require.

FAQ

What is the Strativerse.Ai AI Pine Script Generator?

The Strativerse.Ai AI Pine Script Generator is designed to convert trading ideas described in plain language into Pine Script code. Users can define strategy rules and then review, test, and refine the generated code.

How does Strativerse.Ai use its AI Trading Strategy Generator?

Strativerse.Ai uses its AI Trading Strategy Generator to interpret written trading instructions and translate them into structured strategy code. The process is intended to make early-stage strategy development more accessible and efficient.

Can Strativerse.Ai work as a Trading Strategy Code Generator?

Yes. Strativerse.Ai includes Trading Strategy Code Generator functionality that can convert defined trading rules into Pine Script, Python, or C# code for further review and development.

Can Strativerse.Ai create a Trading Bot From Text?

Strativerse.Ai supports a Trading Bot From Text workflow in which users describe intended trading logic using ordinary language before the platform converts those instructions into code.

Does Strativerse.Ai require advanced coding skills?

Strativerse.Ai is designed to reduce the amount of advanced programming knowledge required to begin developing a strategy. Users should still review generated code carefully and understand the trading logic they intend to implement.

Does Strativerse.Ai support Pine Script?

Yes. Strativerse.Ai supports Pine Script and provides an AI Pine Script Generator intended to help users translate strategy conditions into structured Pine Script code.

Can Strativerse.Ai generate Python or C# strategy code?

Yes. In addition to Pine Script, Strativerse.Ai supports the generation of strategy code in Python and C#, giving users options across different development environments.

Is Strativerse.Ai suitable for testing new trading ideas?

Strativerse.Ai can provide a starting point for translating a new trading concept into code that can subsequently be reviewed and tested. Users remain responsible for validating the strategy and assessing its suitability.

Does Strativerse.Ai guarantee that generated trading strategies will be profitable?

No. Strativerse.Ai generates code based on user-defined instructions, but it does not guarantee trading performance. Market conditions, risk management, strategy design, and testing methodology can all affect results.

Why might traders use Strativerse.Ai for strategy development?

Traders may use Strativerse.Ai to reduce some of the manual coding involved in turning clearly defined trading rules into programmable strategies. The platform is intended to support faster development and iteration while leaving testing and decision-making with the user.

About Strativerse.Ai

Strativerse.Ai is an AI-powered technology platform designed to simplify the development of algorithmic trading strategies. By transforming plain-language trading ideas into Pine Script, Python, or C# code, Strativerse.Ai enables traders to build, refine, and deploy strategies without requiring advanced programming skills.

Media Contact

Organization: strativerse.ai

Contact Person: Daniel Reeves

Website: https://www.strativerse.ai/

Email: Send Email

Address: 128 City Road

City: London

Country: United Kingdom

Release id: 49189

The post Strativerse Ai Launches New AI Pine Script Generator for Faster Strategy Development appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section

file

About Author

Cloud PR Wire

See author's posts

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Related Topics:
Continue Reading

Press Release

PrimeXBT Launches AI-Assisted Trading with MCP Integration, Connecting ChatGPT and Claude to Trading Accounts

Published

19 minutes ago

on

November 4, 2026

By

Castries, Saint Lucia, November 4th, 2026, FinanceWire

PrimeXBT, a global multi-asset broker and crypto asset service provider, has announced the launch of its Model Context Protocol (MCP) integration, enabling traders to connect AI assistants, such as ChatGPT and Claude, directly to their trading accounts. The launch, alongside a new Trading API, expands PrimeXBT’s AI and automation capabilities, introducing new ways for clients to access market information, manage their accounts, and interact with financial markets.

With PrimeXBT MCP, traders can connect their preferred AI assistant using just one link and a PrimeXBT login, without coding or API key configuration. Designed for both new and experienced traders, the integration provides tools, allowing clients to monitor their accounts, explore market prices and charts, review trading history and understand trading conditions through natural-language conversations. Powered by live account data and PrimeXBT’s built-in knowledge base, it delivers relevant, account-specific answers to questions about trading costs, leverage, margin requirements, and platform rules, reducing the need to navigate multiple screens or search for information manually.

MCP also supports AI-assisted trade execution, enabling clients to prepare market, limit, and stop orders and preview estimated prices, fees, margin requirements, leverage, and liquidation levels, calculated by PrimeXBT’s trading engine. Every order requires explicit trader confirmation before execution, with Read-only and Read & Trade permissions available. For added security, the MCP does not allow withdrawals or fund transfers through AI assistants. The integration is available for demo and live accounts on the broker’s PXTrader 2.0 platform, covering CFDs and Crypto Futures.

Commenting on the launch, Jonatan Randin, Senior Market Analyst, said: “AI has become part of everyday life, changing how people access information, use technology and make decisions. We believe trading should evolve in the same direction. With our MCP, we’re bringing real trading data and functionality into the AI assistants people already know and use, making trading more accessible, simplifying complex processes and giving traders greater flexibility in how they interact with markets, while keeping them in control. This is an important step towards a more connected and intuitive trading experience.”

PrimeXBT MCP is built on the broker’s Trading API, which has also been introduced to expand PXTrader 2.0’s capabilities for algorithmic, quantitative and technically experienced traders. The API enables clients to connect their own trading bots, applications and external tools, automate strategies around the clock and access account and market data programmatically. It supports order and position management, custom dashboards and analytics, with security features including two-factor authentication, configurable permissions and optional IP restrictions. Deposits, withdrawals and fund transfers are not supported through the API.

The launch builds on PrimeXBT’s continued development of PXTrader 2.0, its native platform for trading CFDs and Crypto Futures, bringing together advanced trading tools, flexible fiat and crypto funding options, crypto-denominated accounts and competitive trading conditions. As AI continues to transform financial technology, PrimeXBT remains committed to integrating emerging technologies into its trading infrastructure, strengthening its position as a forward-thinking broker and driving the next generation of trading innovation.

To learn more about MCP integration, users can visit PrimeXBT website.

About PrimeXBT

PrimeXBT is a global multi-asset broker and crypto asset service provider trusted by traders in more than 150 countries. The platform bridges traditional and digital markets within one integrated environment, redefining versatility and innovation in online trading. Clients can access Forex, CFDs on indices, commodities, shares, crypto, and Crypto Futures, as well as buy, store, and exchange cryptocurrencies. This unified experience extends across both the native PXTrader 2.0 platform and MetaTrader 5, supported by advanced risk-management tools and a wide range of funding options in crypto, fiat, and local payment methods. Since 2018, PrimeXBT has focused on empowering traders through broad multi-asset access, fair and transparent conditions, professional-grade technology and dedicated human support. By combining expertise, trust, and a client-first approach, PrimeXBT sets a benchmark of excellence in the financial industry and provides traders with the tools they need to trade, grow, and succeed with confidence.

Disclaimer: The content provided here is for informational purposes only and is not intended as personal investment advice and does not constitute a solicitation or invitation to engage in any financial transactions, investments, or related activities. Past performance is not a reliable indicator of future results. The financial products offered by the Company are complex and come with a high risk of losing money rapidly due to leverage. These products may not be suitable for all investors. Before engaging, you should consider whether you understand how these leveraged products work and whether you can afford the high risk of losing your money. The Company does not accept clients from the Restricted Jurisdictions as indicated on its website / T&Cs. Some products and services, including MT5, may not be available in your jurisdiction. The applicable legal entity and its respective products and services depend on the client’s country of residence and the entity with which the client has established a contractual relationship during registration.

Contact

PrimeXBT
pr@primexbt.com

About Author

Cloud PR Wire

See author's posts

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

Joseph Grinkorn: Elon Musk and Starlink Could Take Over the Global Telecom Industry Within Three Years – Traditional Telecom Giants on Notice

Published

33 minutes ago

on

November 4, 2026

By

Morris Group CEO Predicts a Massive Telecommunications Revolution as Satellite Technology Threatens to Make Traditional Cellular Networks Obsolete

NEW YORK, NY, USA – Joseph Grinkorn, investment expert and CEO of Morris Group, is making another bold prediction: Elon Musk’s Starlink could become one of the most powerful forces in global telecommunications, fundamentally changing how the world communicates within the next three years.

Grinkorn believes Musk is preparing to disrupt an industry that has been dominated for decades by traditional mobile carriers and Internet providers. With SpaceX’s rapidly expanding satellite network and Starlink’s direct-to-cell ambitions, the future of telecommunications may no longer depend on thousands of cellular towers and traditional infrastructure.

The numbers show how fast that network is growing. Starlink passed 12 million subscribers by mid-2026 and now operates more than 10,000 satellites in low Earth orbit. In 2025, SpaceX also agreed to acquire EchoStar’s AWS-4 and H-block spectrum licenses in a deal worth about $17 billion. U.S. regulators cleared the sale in May 2026, giving Starlink frequencies of its own for direct-to-cell service.

Grinkorn identifies several reasons why Starlink could become the next global telecommunications powerhouse:

  • The End of Traditional Telecom Dominance: Starlink could challenge the business models of major cellular providers by delivering connectivity directly from space.
  • A Global Mobile Network: Satellite-to-cell technology could eventually allow consumers to connect their smartphones virtually anywhere on Earth. SpaceX has already launched more than 600 direct-to-cell satellites.
  • Internet Without Borders: Starlink has the potential to eliminate geographical limitations and bring high-speed connectivity to underserved markets worldwide. The service already reaches customers in more than 160 countries and territories.
  • A Trillion-Dollar Industry at Risk: Traditional telecommunications companies could face enormous competitive pressure as satellite technology advances.
  • Musk’s Next Billion-Dollar Revolution: Following the overhaul of electric vehicles and commercial spaceflight, Musk could now reshape the global communications industry.
  • The Three-Year Window: Grinkorn believes the next three years could be critical in determining the future leaders of the global telecommunications market.

Joseph Grinkorn’s Statement

“Elon Musk isn’t simply building another Internet company. He’s building the infrastructure for the future of global communications. I believe we are approaching a point where satellites could fundamentally change the way the world connects.

Traditional telecom companies should be very concerned. Starlink has the potential to become a dominant global communications platform, and investors who underestimate this change could miss one of the biggest technological shifts of our generation.”

Grinkorn believes the telecommunications industry is approaching a historic turning point and that Starlink could emerge as one of the most important companies in the global technology and communications market.

What Comes Next

Carriers are already adjusting. EchoStar’s Boost Mobile customers are set to gain access to Starlink’s direct-to-cell service, and T-Mobile has worked with Starlink on satellite texting in the United States. SpaceX has also set a target of user speeds up to 150 Mbps for its upgraded direct-to-cell service.

Watch how fast carriers sign satellite partnerships and how quickly subscriber numbers climb. Those signals will show whether the three-year window Grinkorn describes is opening on schedule.

About Joseph Grinkorn & The Morris Group

Joseph Grinkorn is a Wall Street investment expert and entrepreneur with over 20 years of experience across banking, finance, and real estate. As the founder and CEO of Morris Group, he has built a reputation for accurate market predictions and forward-looking investment strategies. He is frequently featured in the financial press for his insights on equity markets, tariffs, and global trade. Over the past decade, Grinkorn has been actively involved in investments across a broad range of industries and sectors, successfully identifying opportunities and executing some of the most notable private-market transactions across the business and investment landscape.

Founded in 2007, Morris Group is an international investment firm headquartered in New York City. The company operates three divisions: Morris Group Financial, focused on equity investments in technology and social media companies; Morris Group Properties, specializing in high-return real estate investments; and Morris Group Funding, providing commercial financing solutions. With its data-driven approach, transparency, and commitment to growing client returns, Morris Group has established itself as a trusted leader in the investment sector.

Media Contact

Company Name: Morris Group

Phone: (646) 673-8404

Country: United States

Website: www.morris-group.co

About Author

Cloud PR Wire

See author's posts

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

CMS(867.HK/8A8.SG): Ruxolitinib Phosphate Cream Approved in Singapore, Filling Gap in Vitiligo Treatment

Published

33 minutes ago

on

November 4, 2026

By

SHENZHEN, CHINA – China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that its subsidiary, Rxilient Medical received approval from the Health Sciences Authority of Singapore (HSA) on 3 November 2026 for the New Drug Application (NDA) of ruxolitinib phosphate cream (the “Product” or “Lumirix®”) for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age. It is the first and only topical prescription drug in Singapore that directly targets the pathophysiological mechanism of vitiligo[1], meeting a long-standing unmet clinical need.

This approval fills a gap in the field of vitiligo treatment in Singapore. In addition to Singapore, Rxilient Medical has already launched sales of Lumirix® (vitiligo indication) in Hong Kong Special Administrative Region, Macau Special Administrative Region and Taiwan Region.

Since 2022, the Group has launched its “Industry Internationalization” strategy, using Singapore as its business hub in emerging markets to build a highly efficient and collaborative value loop across the entire industry chain of “R&D, production, and sales.” Rxilient Medical is the Group’s commercialization subsidiary for entering emerging markets. With “global localization” as its core strategy, it is committed to bringing innovative global therapies to emerging markets and benefiting local patients through its full-chain commercialization capabilities covering drug import, development, registration, and marketing. Rxilient Medical is operated by a professional and highly experienced localized team. Headquartered in Singapore, the company has established subsidiaries or offices in Hong Kong Special Administrative Region, Taiwan Region, Malaysia, Vietnam, the Philippines, Indonesia, Thailand, and the UAE. By the end of June 2026, Rxilient Medical had achieved sales for a cumulative total of 9 products across multiple countries and regions in Southeast Asia, and had cumulatively submitted marketing applications for more than 20 pharmaceutical products and medical devices, mapping out a robust and continuous product launch blueprint.

About Vitiligo

Vitiligo is a chronic autoimmune disease characterized by depigmentation of the skin, which results from the loss of pigment-producing cells known as melanocytes. It is estimated that approximately 0.7% of Singapore’s population suffers from vitiligo[2]. For decades, dermatologists in Singapore have relied on treatments such as steroids, calcineurin inhibitors, and phototherapy — therapies that fail to specifically or adequately target the pathogenesis of vitiligo. The approval of Lumirix® in Singapore represents the first drug specifically for the regeneration of pigment in non-segmental vitiligo, filling a gap in the field of vitiligo treatment.

More About Ruxolitinib Phosphate Cream

Ruxolitinib phosphate cream (Opzelura®), a novel cream formulation of the selective JAK1/JAK2 inhibitor ruxolitinib developed by Incyte, is the first and only drug approved for the repigmentation of non-segmental vitiligo by the U.S. Food and Drug Administration (FDA)[3]. In the U.S., ruxolitinib phosphate cream is indicated for the topical treatment of non-segmental vitiligo in adult and pediatric patients aged 12 years and older, and for the short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis (AD) in non-immunocompromised patients aged 2 years and older whose disease is not well controlled with topical prescription therapies, or when those therapies are not advisable. In Europe, ruxolitinib phosphate cream is approved for the treatment of non-segmental vitiligo in adults and adolescents aged 12 years and older with facial involvement, and moderate atopic dermatitis in adults whose disease remains inadequately controlled despite treatment with topical corticosteroids and topical calcineurin inhibitors[4].

In January 2026, ruxolitinib phosphate cream was approved for marketing by the National Medical Products Administration (NMPA) of China, becoming the first topical JAK inhibitor approved in China for the treatment of vitiligo, and has since been commercialized in China. Subsequently, in September 2026, the Product was approved for an additional indication of mild to moderate atopic dermatitis (“AD”), for the topical short-term and non-continuous chronic treatment of mild to moderate AD in non-immunocompromised adult and pediatric patients 2 years of age and older whose disease is not adequately controlled with other topical therapies or when those therapies are not advisable. This further expands the Product’s application in the field of dermatological diseases.

In two identical Phase III double-blind, randomized, placebo-controlled studies (TRuE-V1 and TRuE-V2) conducted overseas, the proportion of patients achieving the primary efficacy endpoint of at least 75% improvement in the Facial Vitiligo Area Score Index (F-VASI 75) after 24 weeks of treatment with ruxolitinib phosphate cream was 29.9% in both studies, significantly higher than the 7.5% and 12.9% in the placebo groups, respectively. Continued use up to 52 weeks showed sustained repigmentation[5].

The Group, through a subsidiary of Dermavon, entered into a Collaboration and License Agreement with Incyte for ruxolitinib phosphate cream on 2 December 2022, obtaining an exclusive license to develop, register and commercialize the Product in Mainland China, Hong Kong Special Administrative Region, Macau Special Administrative Region, Taiwan Region and eleven Southeast Asian countries (the “Territory”) and a non-exclusive license to manufacture the Product in the Territory. The subsidiary of Dermavon has sublicensed the relevant rights for the Product outside Mainland China to the Group (excluding Dermavon and its subsidiary).

Incyte has worldwide rights for the development and commercialization of ruxolitinib phosphate cream, marketed in the United States and Europe as Opzelura®. Opzelura® and the Opzelura® logo are registered trademarks of Incyte. Lumirix® is a registered trademark of the Group.

About CMS

CMS is an innovative pharmaceutical company focused on the identification, building, and full lifecycle management of differentiated specialty pharmaceuticals. With a dual-engine approach of in-house R&D and collaborative R&D, and leveraging its core capability to build markets and brands from the ground up, CMS enables each medicine to fully realize both its clinical value and commercial value.

Focusing on unmet clinical needs, CMS efficiently advances the research, clinical development and regulatory approval of differentiated specialty medicines. Drawing on evidence-based medicine and long-standing expertise across specialty therapeutic areas, CMS establishes the medical positioning of its products. Through a professional academic promotion system, CMS drives clinical recognition and large-scale application of its products, translating clinical value into enduring brand competitiveness.

CMS focuses on specialty areas including cardiovascular-kidney-metabolic, central nervous system, gastroenterology, ophthalmology, and skin health. It continuously expands its product portfolio, fostering a tiered structure of marketed products and innovative pipeline candidates, and leverages its solid medical expertise and omni-channel commercialization network to drive the growth of new products. Within the Group, its skin health business, Dermavon, has grown into a leading innovative pharmaceutical company in China’s skin health sector. Meanwhile, CMS is expanding its international business with Southeast Asia as a base, advancing product introduction, registration and commercialization in line with local healthcare needs, while progressively optimizing its regional manufacturing footprint to strengthen localized operations and supply capabilities.

Reference:

1.https://www.straitstimes.com/singapore/health/singapore-studying-efficacy-safety-of-vitiligo-drug-that-is-available-here-via-special-access

2.Chan MF, Thng S. et al. Investigating factors associated with quality of life of vitiligo patients in Singapore, International Journal of Nursing Practice 2013; 19 (Suppl. 3), 3–10

3.The U.S. FDA approval information can be found on the Incyte official website, as follows: https://investor.incyte.com/news-releases/news-release-details/incyte-announces-us-fda-approval-opzeluratm-ruxolitinib-cream

4.The EMA approval information can be found on the Incyte official website, as follows: https://investor.incyte.com/news-releases/news-release-details/incyte-announces-european-commission-approval-opzelurar

5.The clinical studies information can be found on the Opzelura® official website, as follows: https://www.opzelura.com/opzelura-prescribing-information

CMS Disclaimer and Forward-Looking Statements

This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.

This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.

 

Media Contact

Brand: China Medical System Holdings Ltd.

Contact: CMS Investor Relations

Email: ir@cms.net.cn

Website: https://web.cms.net.cn/en/home/

About Author

Cloud PR Wire

See author's posts

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

LATEST POST

Like Us
Follow Us
Subscribe Us
Follow Us